Results 11 to 20 of about 41,528 (187)
Journal of the European Academy of Dermatology and Venereology, Volume 37, Issue 1, Page 93-103, January 2023., 2023 Abstract Background Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizumab in a real‐life setting.
Alessandra Narcisi +19 more
wiley +1 more source
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study
Dermatologic Therapy, Volume 2023, Issue 1, 2023., 2023 Introduction. Psoriasis of the scalp, genital areas, and palms and soles represents a treatment challenge in clinical practice. Randomized clinical trials and real‐life studies investigating the efficacy of biological drugs in these sites are scarce. The present is a descriptive retrospective real‐life study with the aim to evaluate the efficacy and ...
Luca Mastorino +13 more
wiley +1 more source
Headache: The Journal of Head and Face Pain, Volume 62, Issue 8, Page 1029-1038, September 2022., 2022 Abstract Objective The objective of the study was to measure the proportion of patients who consulted for headache and of those who had a final diagnosis of migraine. We also assessed the proportion and characteristics of patients with migraine and the impact of migraine on the daily activities and the professional and social lives of patients visiting
Priscilla Monterrey +11 more
wiley +1 more source
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
Dermatologic Therapy, Volume 35, Issue 5, May 2022., 2022 Abstract Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience.
Luca Mastorino +10 more
wiley +1 more source
Genetic Susceptibility Loci in Genomewide Association Study of Cluster Headache
Annals of Neurology, Volume 90, Issue 2, Page 203-216, August 2021., 2021 Objective Identifying common genetic variants that confer genetic risk for cluster headache. Methods We conducted a case–control study in the Dutch Leiden University Cluster headache neuro‐Analysis program (LUCA) study population (n = 840) and unselected controls from the Netherlands Epidemiology of Obesity Study (NEO; n = 1,457).
Aster V.E. Harder +22 more
wiley +1 more source
, 2008 Headache is among the most frequent neurological symptoms in the Emergency department. Although most of the patients suffer from primary headaches (migraine), an acute headache might be the only symptom of a serious disease, such as subarachnoid ...
Irimia, P. (Pablo) +3 more
core +1 more source
Case Reports in Obstetrics and Gynecology, Volume 2019, Issue 1, 2019., 2019 Posterior reversible encephalopathy syndrome is a rare complication generally associated with headache and acute changes in blood pressure. Delay in the diagnosis and treatment may result in death or in irreversible neurological sequelae. We present three cases of PRES occurring in young women during puerperium.
Eleonora Marcoccia +13 more
wiley +1 more source
Preventive treatment of migraine
Acta Neurológica Colombiana, 2008 Many of the patients with migraine require a preventive therapy to reduce frequency, severity and duration of the crisis, to improve the quality of life, and to improve the responsse to abortive theraphy of attacks. The treatment can be pharmacological,
Ninan T. Mathew.
doaj +2 more sources
Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria
Neurología, 2019 Resumen: OnabotulinumtoxinA ha demostrado ser eficaz como tratamiento preventivo en pacientes con migraña crónica (MC). El Grupo de Estudio de Cefalea de la Sociedad Española de Neurología ha considerado que sería de interés, a los 5 años de la ...
A.B. Gago-Veiga +10 more
doaj +1 more source
Acta Neurológica Colombiana, 2017 INTRODUCCIÓN: Dentro de los estudios poblacionales el grupo de adultos mayores es el de mayor crecimiento y Colombia no está ajena a dicha tendencia, por tanto el estudio de la cefalea en el adulto mayor (>65 años) es un reto diagnóstico y ...
Sergio Francisco Ramírez García +6 more
doaj +1 more source